Research programme: glycogen synthase kinase 3 inhibitors - CrystalGenomics

Drug Profile

Research programme: glycogen synthase kinase 3 inhibitors - CrystalGenomics

Alternative Names: CG-9

Latest Information Update: 31 May 2010

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator CrystalGenomics
  • Class
  • Mechanism of Action Glycogen synthase kinase 3 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Cancer

Most Recent Events

  • 28 May 2010 CrystalGenomics has merged with BexPharm
  • 22 Apr 2009 Preclinical trials in Cancer in South Korea (unspecified route)
  • 22 Apr 2009 Pharmacodynamics data from a preclinical trial in Cancer presented at the 100th Annual Meeting of the American Association for Cancer Research (AACR-2009)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top